Compare EVLV & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | WVE |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.7M | 1.0B |
| IPO Year | 2020 | 2015 |
| Metric | EVLV | WVE |
|---|---|---|
| Price | $5.06 | $4.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $9.13 | ★ $29.81 |
| AVG Volume (30 Days) | 1.8M | ★ 3.3M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,905,000.00 | $3,704,000.00 |
| Revenue This Year | $21.67 | N/A |
| Revenue Next Year | $19.50 | $85.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 40.48 | ★ 149.43 |
| 52 Week Low | $4.61 | $4.84 |
| 52 Week High | $8.81 | $21.73 |
| Indicator | EVLV | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 38.21 |
| Support Level | $4.87 | N/A |
| Resistance Level | $5.86 | $6.33 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 0.01 | 19.86 |
Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.